When was RespireRx Pharmaceuticals founded?

RespireRx Pharmaceuticals was founded in 1987 and raised its 1st funding round 21 years after it was founded.

Where is RespireRx Pharmaceuticals located?

RespireRx Pharmaceuticals is headquartered in Glen Rock, United States.

How many employees does RespireRx Pharmaceuticals have?

As of Aug 31, 2026, the latest employee count at RespireRx Pharmaceuticals is 5.

Is RespireRx Pharmaceuticals a funded company?

RespireRx Pharmaceuticals is a funded company, having raised an undisclosed amount across 15 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Sep 16, 2008.

When was the latest funding round of RespireRx Pharmaceuticals?

RespireRx Pharmaceuticals' latest funding was a $***** Grant (prize money) round on Sep 23, 2025, with participation from 1 investor. Its primary sector is Pulmonology. In United States, the Pulmonology sector has seen $962M in funding in 2026 to date.

What is the annual revenue of RespireRx Pharmaceuticals?

Annual revenue of RespireRx Pharmaceuticals is less than $1M as on Dec 31, 2015

Where does RespireRx Pharmaceuticals rank among its competitors?

RespireRx Pharmaceuticals ranks 412th amongst 2532 active competitors, of which 859 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of RespireRx Pharmaceuticals?

RespireRx Pharmaceuticals' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

RespireRx Pharmaceuticals - 2026 Company Profile, Funding, Competitors & Financials

RespireRx Pharmaceuticals is a public company based in Glen Rock (United States), founded in 1987. It operates as a Developing innovative treatments for disorders caused by disruption of neuronal signaling. RespireRx Pharmaceuticals has raised an undisclosed amount in funding. The company has 2532 active competitors, including 859 funded and 631 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developing innovative treatments for disorders caused by disruption of neuronal signaling, a biopharmaceutical company focused on creating revolutionary treatments. The company is dedicated to combating disorders arising from disrupted neuronal signaling. It develops pharmaceutical cannabinoids and neuromodulators. Their research and development efforts are centered on addressing conditions like obstructive sleep apnea, attention deficit hyperactivity disorder (ADHD), spinal cord injury (SCI), epilepsy, and pain. The company utilizes platforms like AMPAkines and GABAkines to target neurotransmission resolution. They aim to provide solutions for unmet medical needs through innovative pharmaceutical development.

Website: respirerx.com
Social

Key Metrics

Founded Year

1987

Location

Glen Rock, United States

Stage

Public

Latest Funding Round

Grant (prize money), Sep 23, 2025, $*****

Investors

Illinois Ventures & 3 more

Ranked

412^th among 2532 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2015

Employee Count

5 as on Aug 31, 2026

Investment & Acquisitions

Pier Pharmaceuticals

Similar Companies

Savara Pharma & 139 more

Exit Details

Public

View RespireRx Pharmaceuticals' full profile

RespireRx Pharmaceuticals is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
RESPIRERX PHARMACEUTICALS INC. CIN: 849636 , United States, Active	Feb 09, 1987	$0 - $1M (As on Dec 31, 2015)	2 (As on Dec 31, 2021)	-

RespireRx Pharmaceuticals got listed on Nov 10, 1989.

Click here to take a look at RespireRx Pharmaceuticals's IPO in detail

RespireRx Pharmaceuticals has raised funding over 15 rounds. Its first funding round was on Sep 16, 2008. Its latest funding round was a Grant (prize money) round on Sep 23, 2025 for $*****. 1 investor participated in its latest round. RespireRx Pharmaceuticals has 4 institutional investors.

Here is the list of recent funding rounds of RespireRx Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 23, 2025	5850326	Grant (prize money)	7637611	6020177	2653326	7633174
Sep 23, 2025	5048204	Grant (prize money)	3274365	5457059	1847423	HHS
Aug 12, 2020	8374117	Post IPO	3805846	2585682	6370670	9833704

Access funding benchmarks and valuations. Sign up today!

View details of RespireRx Pharmaceuticals's funding rounds and investors

RespireRx Pharmaceuticals' employee count trend

RespireRx Pharmaceuticals has 5 employees as of Aug 26. Here is RespireRx Pharmaceuticals's employee count trend over the years:

Employee count trend for RespireRx Pharmaceuticals

Uncover RespireRx Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of RespireRx Pharmaceuticals include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of RespireRx Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Celularity 2016, Warren (United States), Public	Developer of allogeneic cell therapies to treat multiple diseases	$290M	Celgene, Dreyfus Family Office & 8 others	71/100
412th	RespireRx Pharmaceuticals 1987, Glen Rock (United States), Public	Developing innovative treatments for disorders caused by disruption of neuronal signaling	-	Illinois Ventures, NINDS & 2 others	51/100